The effect of vitamin D on insulin resistance in patients with type 2 diabetes

Afsaneh Talaei1*, Mahnaz Mohamadi2 and Zahra Adgi2

Abstract

Introduction: Over the past decade, numerous non-skeletal diseases have been reported to be associated with vitamin D deficiency including type2 diabetes mellitus (T2DM). Different studies provide evidence that vitamin D may play a functional role in glucose tolerance through its effects on insulin secretion and insulin sensitivity. This study evaluates the effects of vitamin D supplementation on insulin resistance in T2DM.

Method: Through a before-after study, 100 patients with T2DM, 30–70 years old, were recruited from an Arak diabetes clinic as consecutive attenders. Participants were assessed for clinical and biochemistry. Serum insulin and, 25(OH)D concentration, and HOMA-IR was calculated. All measurements were performed at the beginning and the end of the study. Patients received 50,000 unit of vitamin D$_3$ orally per week for eight weeks, Statistical analysis was made using SPSS17. The results were analyzed by descriptive tests, and a comparison between variables were made using paired T-tests or Wilcoxon tests, as appropriate.

Results: 100 participants including 70 women (70%) and 30 men (30%) took part in the study. All results were presented as Mean±SD, or medians of non-normally distributed.

24% of the participants were Vitamin D deficient (serum 25(OH)D ≤ 20 ng/ml(50 nmol/l)).
Mean serum 25 (OH) D concentration was 43.03± 19.28 ng/ml (107.5±48.2 nmol/l).

The results at baseline and at the end, for FPG were 138.48±36.74 and 131.02±39 mg/dl (P=0.05), for insulin, 10.76±9.46 and 8.6±8.25 μIU/ml (P=0.028) and for HOMA-IR, 3.57±3.18 and 2.89±3.28 (P=0.008) respectively.

Conclusion: Our data showed significant improvements in serum FPG, insulin and in HOMA-IR after treatment with vitamin D, suggested that vitamin D supplementation could reduce insulin resistance in T2DM.

Keywords: Diabetes, Insulin resistance, Vitamin D

Introduction

Over recent decades, numerous non-skeletal diseases associated with vitamin D deficiency have been reported including T2DM(type2 diabetes mellitus) [1].

T2DM and vitamin D deficiency have risk factors in common such as American-African race, obesity, aging and low physical activity [2]. Also there are associations of vitamin D deficiency with diseases such as osteoporosis, cardiovascular disease and metabolic syndrome disorders diseases [3-5].

Some studies have shown a relationship between vitamin D deficiency and T2DM [6]. Also some other studies have shown that vitamin D may play a functional role on glucose tolerance through its effects on insulin secretion and insulin sensitivity [7].

In comparison to healthy controls, subjects with T2DM have significantly lower circulating concentration of 25 (OH)D [8]. Also the prevalence of vitamin D deficiency in women with T2DM is more common and also, old men with vitamin D deficiency, secret higher insulin after glucose intake [9,10].

Animal studies have shown that vitamin D is a basic factor, necessary for normal insulin secretion [11,12]. Vitamin D reduces insulin resistance probably through its effect on calcium and phosphorus metabolism and through up regulation of the insulin receptor gene [13].

One study on 5,677 subjects with impaired glucose tolerance showed that vitamin D supplementation increased insulin sensitivity by 54% [14]. Other studies also found...
that increased vitamin D intake improves insulin sensitivity [15,16].

Another study on 126 healthy people showed that there is a direct relation between insulin sensitivity and 25(OH)D level and that vitamin D deficiency had a negative effect on β-cell function in pancreatic β-cells [17]. One follow-up study, through 20 years on 4,843 patients with T2DM, showed that vitamin D intake was associated with reduced prevalence of the T2DM [18]. T2DM is considered to develop from a state of increased insulin resistance and β-cell dysfunction [19]. Studies on associations between insulin secretion and serum 25(OH)D have been inconsistent. We have evaluated the effects of vitamin D supplementation on insulin resistance in subjects with T2DM.

Methods

Through a before and after matched, single blind study, 100 patients with T2DM aged 30–70 years old, were on a diet (more intake of vegetables and fruits and limited use of bread and rice that are usual foods in Iran) or taking oral hypoglycemic agents (glibenclamide or repaglinide +metformin or only metformin), referred to a diabetes clinic at Arak medical university hospital, participated in the study following invitation of consecutive clinical attenders. The patients took part in the study for eight weeks. We added vitamin D₃ to their medication and recorded their demographic data and medication before and after supplementation. During the trial, the subjects were instructed not to change their diabetes drugs or diet. Participants were assessed for height, weight, and BMI. FPG (Fasting Plasma Glucose) and HbA1c were measured by enzymatic and chromatographic methods using commercial kits (Bio-system S.A and Human Germany) respectively. We also measured serum creatinine, lipid profiles (TC (Total Cholesterol), TAG (Triacylglyceride), HDL (High Density Lipoprotein) and LDL (Low Density Lipoprotein)), insulin, Ca (Calcium), P (Phosphorous) and ALP (Alkaline Phosphatase). Serum 25(OH)D was measured by radioimmunoassay (RIA) (kits manufactured by Biosource Europe SA, Belgium). HOMA-IR (Hemostatic model assessment-Insulin resistance) was calculated based on following formula [20]:

\[
HOMA-IR = \frac{FPG (\text{mmol/L}) \times \text{Insulin} (\mu \text{IU/ml})}{22.5}
\]

We also assessed liver function by measuring serum concentration of AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase) to rule out liver disease and major non alcoholic fatty disease of the liver as exclusion criteria that might affect vitamin D metabolism. Inclusion criteria were absence of hepatic, renal and bone diseases, malignancy, any history of the use of drugs such as insulin, anticonvulsants, calcium, vitamin D and an HbA1c <8% for the last three months. Written consent was obtained from all participants. After baseline assessment all patients took 50,000 units

| Variable | Before treatment | After treatment | P-value |
|----------|------------------|----------------|---------|
| FPG (mg/dl) | 138.48±36.74 | 131.02±39 | 0.05 |
| (mmol/l) | 7.6±2.04 | 7.27±2.16 | |
| Insulin (µIU/ml) | 10.76±8.9 | 8.6±8.25 | 0.02 |
| HOMA-IR | 3.57±3.18 | 2.89±3.28 | 0.008 |
| 25(OH)D (ng/ml) | 43.03±19.28 | 60.12±17.2 | 0.02 |
| (nmol/l) | 107.5±48.2 | 150.3±43 | |

Table 3 Comparison of biochemical characteristics (mean ± SD) in patients with diabetes type 2 before and after treatment with vitamin D for 8 weeks

| Variable | Before treatment | After treatment | P-value |
|----------|------------------|----------------|---------|
| FPG (mg/dl) | 191.1±32.2 | 180.2±31.0 | 0.3 |
| (mmol/l) | 234.4±73.3 | 201.0±65.1 | 0.2 |
| TAG | 109.5±26.4 | 103.0±23.2 | 0.5 |
| LDL-C | 42.5±8.1 | 38.2±7.2 | 0.3 |
| HDL-C | 70.5±10.1 | 63.8±7.3 | 0.4 |

Table 2 The effects of vitamin D supplementation on FBS, insulin and HOMA-IR at different baseline vitamin D concentration (Drop line plot of vitamin D)

| Variable | Vitamin D <20 (n=20) | Vitamin D 20–30 (n=10) | Vitamin D 30–45 (n=15) |
|----------|-----------------------|------------------------|---------------------|
| FBS (mg/dl) | 154±31.9 | 148±44.9 | 146±42.3 |
| (µIU/ml) | 10.16±9.2 | 9.1±6.1 | 8.7±10.1 |
| HOMA-IR | 3.6±1.2 | 3.05±1.6 | 3.2±4.05 |
| Variable | Vitamin D 40–60 (n=45) | Vitamin D>60 (n=10) |
|----------|-----------------------|---------------------|
| FBS (mg/dl) | 131±34.6 | 120±35.6 |
| (µIU/ml) | 118±9.8 | 7.5±7 |
| HOMA-IR | 3.6±3.05 | 2.2±2.6 | 2.6±2.09 | 1.79±1.38 | 0.4 |
of vitamin D₃ weekly, for 2 month. During the treatment, all patients were visited and interviewed about possible side effects, and to determine the degree of compliance. After 2 months of treatment, all laboratory tests and clinical evaluations were repeated as per the initial visit. Patient compliance was assessed by tablet counts at each visit in reports.

The Medical Ethics Committee of Arak medical university approved the study protocol which complied with the current version of the Declaration of Helsinki. Statistical analysis was performed using Statistics Package for Social Science (SPSS version 13, SPSS Inc., Chicago, IL, USA). The data were analyzed by descriptive tests such as mean, SD (standard deviation), and SE (Standard Error) and K-S (Kolmogorov-Smirnov) tests were performed to assess the normality of the variables before further statistical analysis. All data in this study are presented as mean± SD.

The effects of Vitamin D supplementation on the variables were analyzed by paired t-test (for normally distributed) or Wilcoxon test (for non-normally distributed). Step-wise linear regression analysis was used to provide models for predicting of FPG, insulin and HOMA-IR, after vitamin D supplementation. Baseline 25(OH)D was used in the models.

### Results

100 patients (70 women and 30 men) participated in this study. The mean age of the participants was 54.1±11 years old. The mean weight of the patients at baseline was 70±12 and at the end was 71±05 kg that doesn't have meaningful differences. 92% were controlled with oral hypoglycemic agents either as monotherapy or in combination therapy (including glibenclamide, metformin and repaglinide) and 8% were on alone diet. Mean 25 (OH) D concentration was 43.03±19.28 ng/ml (107.5±48.2 nmol/l) at baseline and 24% of subjects at baseline were vitamin D deficient based on 25 (OH) D<20 ng/ml (50 nmol/l). FPG before and after treatment was normally distributed, so it was analyzed by paired t test. But HOMA-IR and insulin before and treatment were non-normally distributed, so they were analyzed by Wilcoxon test. FPG and insulin concentration decreased significantly after treatment with vitamin D₃ (P=0.05). Comparison of mean for HOMA-IR and insulin before and treatment were non-normally distributed, so they were analyzed by Wilcoxon test. FPG and insulin concentration decreased significantly after treatment with vitamin D₃ (P=0.05). Comparison of mean for HOMA-IR before and after treatment with vitamin D showed a meaningful reduction after supplementation (Table 1). We stratified baseline serum 25(OH)D and reported the changes in each variable for each stratum by plotting the changes in each variable (Table 2).

Eight weeks of vitamin D supplementation did not change mean serum concentration of TC, TG, HDL or LDL cholesterol, vs baseline (Tables 3).

By using linear regression analysis, we suggest a model for predicting FPG after supplementation with vitamin D. We showed that the effect of vitamin D was to reduce FPG 30% (Tables 4,5,6).

### Table 4 Model for prediction of final FPG after treatment with vitamin D for 8 weeks in 100 patients with type 2 diabetes

| Model       | Unstandardized coefficients | Standardized coefficients | Sig | R Square change |
|-------------|-----------------------------|---------------------------|-----|-----------------|
| Constant    | 0.337                       |                           | 0.991 |                 |
| FBS−1       | 0.460                       | 0.434                     | 0.00 | 0.032           |
| Vitamin D   | −0.394                      | −0.195                    | 0.022 |                 |
| gender      | 16.488                      | 0.195                     | 0.020 |                 |
| HbA1C       | 7.024                       | 0.184                     | 0.031 |                 |

Model: FBS₂ = 0.46 × FBS₁ + 0.39 × Vitamin D + 16.4 × Gender + 7.02 × HbA₁C + 0.33.

FPG₁: Baseline fasting plasma glucose.

Vitamin D: Baseline 25(OH)D.

### Table 5 Model for prediction of fasting serum Insulin after treatment with vitamin D in 100 patients with type 2 diabetes for 8 weeks

| Model       | Unstandardized coefficients | Standardized coefficients | Sig | R Square change |
|-------------|-----------------------------|---------------------------|-----|-----------------|
| Constant    | 9.332                       |                           | 0.000 |                 |
| Insulin 1   | 0.258                       | 0.296                     | 0.002 | 0.036           |
| 25(OH) D    | −0.082                      | −0.191                    | 0.048 |                 |

Model: Insulin 2 = 0.25 × Insulin 1 + 0.08 × Vitamin D + 9.33.

Vitamin D: Baseline 25(OH)D.

Insulin 1: Baseline insulin.
Table 6 Model for prediction of HOMA-IR after treatment with vitamin D

| Model          | Unstandardized coefficients | Standardized coefficients | Sig | R Square change |
|----------------|-----------------------------|---------------------------|-----|-----------------|
| Constant       | 3.432                       |                           | 0.00|                 |
| HOMA_IR_1      | 0.276                       | 0.268                     | 0.006| 0.043           |
| Vitamin D      | -0.035                      | -0.208                    | 0.031|                 |

Model: HOMA-IR = 0.27 × HOMA-IR 1 0.03 × Vitamin D + 3.43.
Vitamin D: Baseline 25(OH)D.
HOMA-IR-1: Baseline HOMA-IR.

Discussion

The main purpose of this study was to investigate the effects of vitamin D supplementation on glucose homeostasis. The results showed that vitamin D supplementation significantly decreased serum FPG, insulin and HOMA-IR in patients with T2DM.

The role of basal serum FPG and vitamin D, sex, and HbA1c in predicting FPG final was 36%. There was an interesting finding. There was an inverse relation between final FPG and basal 25(OH)D concentration. In other words, higher serum basal 25(OH)D led to lower final FPG. This means that who had a higher serum basal 25(OH)D concentration benefited more of vitamin D intake to lowering final FPG. This may be because of non-skeletal effects of vitamin D which appears in higher vitamin D concentration and the effects of lower vitamin D concentration, are limited to the bone and muscle. Our data showed that effects of vitamin D on insulin resistance was significant when vitamin D concentration was 40–60 ng/ml(100–150 nmol/l) and in lower and upper vitamin D concentration, it didn’t affect on insulin resistance.

Effects of vitamin D supplementation on glucose homeostasis have been shown in numerous studies. Our findings are consistent with results of many other published studies, in which the insulin resistance appears to be decreased in T2DM patients who had received vitamin D. For example, Inzucchi showed a 60% improvement in insulin sensitivity by increased serum 25(OH)D concentration from 10 to 30 ng/ml(25 to 75 nmol/l), by which metformin or troglitazone were 54% and 13% respectively [14]. Von Hurst (2009) showed that vitamin D supplementation significantly improved insulin sensitivity and insulin resistance [21]. Ken (2004) found an inverse relation between 25(OH) vitamin D concentration and FPG, but a direct relation with insulin sensitivity [17].

As to these studies, our study shows that mean FPG was significantly reduced after increased vitamin D intake. Monthly supplementation with 120,000 units of vitamin D also improved insulin sensitivity [22]. Although in contrast to some studies, there was a significant reduction in HOMA-IR after taking vitamin D, Witham foundout that vitamin D intake (at different dosage) had no effects on insulin resistance or on HbA1c [23] as did Lind [24]. Nagpal reported that vitamin D supplementation had no effect on mean of insulin sensitivity but two years treatment with vitamin D did improve HOMA-IR [25].

There are some mechanisms for the effects of vitamin D: presence of vitamin D receptors on pancreatic β cells [1]. Vitamin D activating 1α hydroxylase is expressed in pancreatic β cells [26], presence of vitamin D response element in the insulin gene [27], presence of vitamin D receptor in skeletal muscle [28] and the fact that 1,25(OH)D increases transcription of insulin receptor genes [13], and also suppresses the renin gene reducing hyperglycemic-induced increases in renin levels in pancreatic β cells and blockade of renin-angiotensin activity has been proposed as a novel target for diabetes treatment [29].

Protective effects of vitamin D on diabetes, maybe due to well known effects of vitamin D such as its anti-inflammatory properties, its effects on calcium and phosphorus metabolism and regulation of the insulin receptor gene [13]. It seems that vitamin D increases in calcium content of the cells, in turns leading to increased transport of glucose into the muscle [30]. Vitamin D also regulates nuclear PPAR (Peroxisome proliferative activated receptor) that has an important role in the insulin sensitivity [31], vitamin D deficiency is associated with increases in inflammation. Vitamin D attenuates the expression of proinflammatory cytokines involved in insulin resistance such as interleukins, IL-1, IL-6, TNF-a, also down regulates NF-Kb (Nuclear factor) activity [32].

It would be useful, though to undertake further studies to discover more about the mechanism and the effect of vitamin D on both alpha and islet beta-cell function and also on the mechanisms determining insulin resistance.

Some Iranian studies also showed that calcitriol [33], vitamin D injection [34] and vitamin D intake couldnt affect on diabetes and insulin resistance [35]. Although some of them reported significant effects of vitamin D on diabetes [36].

A limitation of our study is that we did not evaluate the effects of placebo on FPG, insulin or HOMA-IR. However, there are a few studies that didn’t use placebo, evaluated the effects of vitamin D at different doses on glucose homeostasis [21].
Conclusion
It seems that vitamin D can improve diabetes control and it is recommended that vitamin D supplementation should be included in treatment of type 2 diabetes.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
AT carried out the design of the study, participated in the coordination of the study and drafted the manuscript. MM performed the statistical analysis and helped to draft the manuscript. ZA participated in the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
1Thyroid Disorders Research Center, Arak University of Medical Sciences, Arak, Iran. 2Department of Endocrinology, Arak University of Medical Sciences, Arak, Iran.

Received: 30 May 2012 Accepted: 20 February 2013

References
1. Zittermann A: Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006, 92:39–48.
2. Alvarez JA, Ashraf A: Role of vitamin D in insulin secretion and insulin sensitivity for glucose homoeostasis. Int J Endocrinol 2010, 2010:31–38.
3. Yingying S, Ling Y: Can vitamin D intake assist in improving the outcome of endodontic treatment for diabetic patients. Medical Hypotheses 2009, 2:1–6.
4. Foss YJ: Vitamin D deficiency is the cause of common obesity. Med Hypotheses 2009, 72:314–321.
5. Zhang Z, Zhang Z: Comment on vitamin D deficiency is the cause of common obesity. Med Hypotheses 2009, 73:123.
6. Mattila C, Knett P, Mannisto S, et al: Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007, 30:2569–2570.
7. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D: Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008, 10:185–197.
8. Petschmann P, Scherenthaler G, Wobusczuk W: Serumosteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 1988, 31:892–895.
9. Isaia G, Gorgino F, Adami S: High Prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 2001, 24:1496.
10. Baynes KC, Boucher BJ, Feskins EJ, Kromhout D: Vitamin D, glucose tolerance andinsulinemia in elderly men. Diabetesologia 1997, 40:344–347.
11. Tanaka Y, Seino Y, Ishida M: Effects of vitamin D3 on the pancreatic secretion of insulin and somatostatin. Acta Endocrinol 1984, 105:528–553.
12. Chertow BS, Szivit NZ, Baranetsky NG, Clark SA, Waite A: Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 1983, 113:1511–1518.
13. Maestro B, Molero S, Bajo S: Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell bio-chemfuncnt 2002, 20:227–232.
14. Inazuchi SE, Maggs DG, Spollett GR: Efficacy and metabolic effect of metformin and troglitazone in type 2 diabetes mellitus. N Engl J Med 1998, 338(13):867–872.
15. Gedin O, Akalin S: Effects of vitamin D deficiency and repletion on insulin and glucagonsecretion in man. Diabetologia 1986, 29(3):142–145.
16. Cade C, Norman AW: Vitamin D3 impairs improved glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986, 119(1):84–90.
17. Ken Chiu C, Audrey C: Hypovitaminosis D is associated with insulin resistance and Bcell dysfunction. Am J Clin Nutr 2007, 79(5):820–825.
18. Zehra O, Tahir Sh A: vitamin D deficiency and type 2 diabetes. Postgrad Med J 2010, 86:18–25.
19. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(1):37–42.
20. Tanabe N, Saito K, Yamada Y: Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes. Inter Med 2009, 48:401–409.
21. von Hurst PR, Stonehouse W, Coad J: vitamin D supplementation reduces insulin resistance in south Asian Women living in New Zealand. Br J Nutr 2009, 28:1–7.
22. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B: The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non-diabetic adults. Diabetes Care 2007, 30(4):980–986.
23. Witham MD, Dow FJ, Druburgh M, Sugden JA, Morris AD, Struthers AD: The effect of different doses of vitamin D3 on markers of vascular health. Diabetologia 2010, 53(10):2112–2119.
24. Lind L, Pollare T, Hwarzfrer A, Lihell H, Sörensen OH, Ljungshll S: Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance, Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 1989, 11(1):141–147.
25. Nagpal J, Pande JN, Bhartia A: A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabetic Medicine 2009, 26(1):19–27.
26. Bland R, Markovic D, Hils CE, Hughes SW, Chan SL, Squares PE, et al: Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid BiochemMol Biol 2004, 89(1–10):121–125.
27. Maestro B, Davila N, Caranza MC, Calle C: Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid BiochemMol Biol 2003, 84(2–3):223–230.
28. Simpson RJ, Thomas GA, Arnold AJ: Identification of 1, 25-dihydroxyvitamin D3 receptors and activities in muscle. J Biological Chemistry 1985, 260(15):8882–8891.
29. Cheng Q, Li YC, Boucher BJ, Leung PS: A novel role for vitamin D: modulation of expression and function of the local renin–angiotensin system in mouse pancreatic islets. Diabetologia 2011, 54:2077–2081.
30. Ojuka E: Role of calcium AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. ProcVnscoc 2004, 63:275–278.
31. Dunlop TW, Vaishan S, Frank C, Molkar F, Sinkkoren L, Calberg C, et al: The human peroxisome proliferator-activated receptor α gene is a primary target of 1α, 25-dihydroxyvitamin D3 and its nuclear receptor. J Molecular Biology 2005, 349(2):248–260.
32. Cohen-Lahav M, Douvdavani A, Chaimovz C, Shany S: The anti-inflammatory activity of 1,25 dihydroxy vitamin D3 in macrophages. J Steroid BiochemMol Biol 2007, 103(5):558–562.
33. Bonakdaran S, Afkhami Zadeh M: Effect of Calcitriol on Glycemic and Lipid Control in Type 2 Diabetes. Iran J Endocrinol Metab 2011, 12(5):513–519.
34. Heshrat M, Tabatabaei E, Moradzade K, Abbaszade S: The effect of parenteral vitamin D supplementation on insulin resistance and anthropometric factors in patients with diabetes type 2. Iran J Diabetes Lipid Dis 2011, 10(3):492–503.
35. Behradmanesh S, Rouhani K, Baradaran A: Effect of Supplementary Vitamin D on Improvement of Glycemic Parameters in Patients with Type 2 Diabetes. J Isfahan Med Sch 2011, 29(151):1098–1105.
36. Nikoyehy B, Neyestani T, Farvid M, Alavimajd H, Kalayi A, Shariat Zadeh N, et al: Effects of daily consumption of Iranian yoghurt drink doogh fortified with vitamin D or vitamin D plus calcium on the anthropometric and glycemnic indices in type-2 diabetes patients. Iran J Nutr Sci Food Technol 2011, 6(3):20–29.